G Rhys Williams
Overview
Explore the profile of G Rhys Williams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martins R, Kadakia A, Williams G, Milanovic S, Connolly M
J Clin Psychiatry
. 2023 Aug;
84(5).
PMID: 37555674
To estimate the fiscal consequences of schizophrenia compared to the general US population using a "government perspective" fiscal analytic modeling framework capturing lost tax revenue and broader government costs in...
2.
Mehta D, Lee I, Liu H, DeKoven M, Wensel B, Williams G
J Comp Eff Res
. 2022 Nov;
11(17):1293-1308.
PMID: 36331060
To compare all-cause and epilepsy-specific pharmacy and total costs associated with initiation of eslicarbazepine acetate (ESL) or brivaracetam (BRV) among patients with focal seizures in long-term care (LTC) in the...
3.
Kadakia A, Catillon M, Fan Q, Williams G, Marden J, Anderson A, et al.
J Clin Psychiatry
. 2022 Oct;
83(6).
PMID: 36244006
The economic burden of schizophrenia in the United States (US) was estimated at $155.7 billion in 2013. Since 2013, the US experienced significant health care reforms and treatment advances. This...
4.
Kadakia A, Brady B, Dembek C, Williams G, Kent J
Am J Manag Care
. 2022 Sep;
28(9):e315-e324.
PMID: 36121363
Objectives: Extrapyramidal symptoms (EPS) affect 15% to 30% of patients with schizophrenia treated with antipsychotics and have been associated with poor outcomes. This study examined the incidence and economic burden...
5.
Thach A, Kirson N, Zichlin M, Dieye I, Pappert E, Williams G
J Health Econ Outcomes Res
. 2022 Feb;
8(2):82-92.
PMID: 35178465
"On-demand" treatments approved in the United States (US) for "OFF" episodes in Parkinson's disease (PD) include apomorphine hydrochloride injection (SC-APO), apomorphine sublingual film (APL), and levodopa inhalation powder (CVT-301). APL...
6.
Thach A, Zichlin M, Kirson N, Yang K, Gaburo K, Pappert E, et al.
J Comp Eff Res
. 2022 Jan;
11(4):285-295.
PMID: 35068168
To compare efficacy of apomorphine sublingual film (APL) and levodopa inhalation powder (CVT-301) for 'on-demand' treatment of Parkinson's disease 'OFF' episodes. Patient-level data from an APL pivotal study were re-weighted...
7.
Kadakia A, Fan Q, Shepherd J, Dembek C, Bailey H, Walker C, et al.
Schizophr Res Cogn
. 2022 Jan;
28:100233.
PMID: 35004189
Objective: The objective was to investigate the association between cognitive impairment and healthcare resource utilization (HCRU) and quality of life (QoL) among patients with schizophrenia. Methods: Data from the Adelphi...
8.
Blaylock B, Niu X, Davidson H, Gravenstein S, DePue R, Williams G, et al.
Ann Pharmacother
. 2021 Dec;
56(8):878-887.
PMID: 34963317
Background: Assessing chronic obstructive pulmonary disease (COPD) severity is challenging in nursing home (NH) residents due to incomplete symptom assessments and exacerbation history. Objective: The objective of this study was...
9.
Kadakia A, Brady B, Dembek C, Williams G, Kent J
J Med Econ
. 2021 Dec;
25(1):87-98.
PMID: 34913797
Background: Extrapyramidal symptoms (EPS) are common side-effects of second-generation antipsychotics (SGA), that can negatively impact patient quality-of-life, and are associated with increased morbidity and mortality. This study examined the incidence...
10.
Kadakia A, Fan Q, Shepherd J, Bailey H, Dembek C, Walker C, et al.
Curr Med Res Opin
. 2021 Nov;
38(3):469-478.
PMID: 34812100
Objective: The objective of this survey was to assess patient outcomes and caregiver status by disease severity among patients with schizophrenia in the United States. Methods: A point-in-time survey was...